• +1-646-491-9876
    • +91-20-67278686

    Search

    Osteoarthritis-Pipeline Review H2 2017

    Osteoarthritis-Pipeline Review H2 2017

    • Report Code ID: RW00011022660
    • Category Life Sciences
    • No. of Pages 240
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Osteoarthritis-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

    Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

    Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
    -The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 6
    Osteoarthritis-Overview 7
    Osteoarthritis-Therapeutics Development 8
    Osteoarthritis-Therapeutics Assessment 21
    Osteoarthritis-Companies Involved in Therapeutics Development 31
    Osteoarthritis-Drug Profiles 61
    Osteoarthritis-Dormant Projects 213
    Osteoarthritis-Discontinued Products 219
    Osteoarthritis-Product Development Milestones 221
    Appendix 229

    List of Tables
    Number of Products under Development for Osteoarthritis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Products under Development by Companies, H2 2017 (Contd..4), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Osteoarthritis-Pipeline by 4P-Pharma SAS, H2 2017
    Osteoarthritis-Pipeline by AbbVie Inc, H2 2017
    Osteoarthritis-Pipeline by Abiogen Pharma SpA, H2 2017
    Osteoarthritis-Pipeline by Ablynx NV, H2 2017
    Osteoarthritis-Pipeline by Amgen Inc, H2 2017
    Osteoarthritis-Pipeline by Amura Holdings Ltd, H2 2017
    Osteoarthritis-Pipeline by Anterogen Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Asahi Kasei Pharma Corp, H2 2017
    Osteoarthritis-Pipeline by Axsome Therapeutics Inc, H2 2017
    Osteoarthritis-Pipeline by Biopharm GmbH, H2 2017
    Osteoarthritis-Pipeline by Bone Therapeutics SA, H2 2017
    Osteoarthritis-Pipeline by Can-Fite BioPharma Ltd, H2 2017
    Osteoarthritis-Pipeline by Cardax Inc, H2 2017
    Osteoarthritis-Pipeline by Cellular Biomedicine Group Inc, H2 2017
    Osteoarthritis-Pipeline by Corestem Inc, H2 2017
    Osteoarthritis-Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Eli Lilly and Company, H2 2017
    Osteoarthritis-Pipeline by Evgen Pharma Plc, H2 2017
    Osteoarthritis-Pipeline by Galapagos NV, H2 2017
    Osteoarthritis-Pipeline by Gemphire Therapeutics Inc, H2 2017
    Osteoarthritis-Pipeline by Genequine Biotherapeutics GmbH, H2 2017
    Osteoarthritis-Pipeline by GlaxoSmithKline Plc, H2 2017
    Osteoarthritis-Pipeline by InKemia IUCT Group SA, H2 2017
    Osteoarthritis-Pipeline by International Stem Cell Corp, H2 2017
    Osteoarthritis-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
    Osteoarthritis-Pipeline by K-Stemcell Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Kang Stem Biotech Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Lateral Pharma Pty Ltd, H2 2017
    Osteoarthritis-Pipeline by Levolta Pharmaceuticals Inc, H2 2017
    Osteoarthritis-Pipeline by LG Chem, Ltd., H2 2017
    Osteoarthritis-Pipeline by Marina Biotech Inc, H2 2017
    Osteoarthritis-Pipeline by Medivir AB, H2 2017
    Osteoarthritis-Pipeline by Merck KGaA, H2 2017
    Osteoarthritis-Pipeline by Mesoblast Ltd, H2 2017
    Osteoarthritis-Pipeline by Mor Research Application Ltd, H2 2017
    Osteoarthritis-Pipeline by Nordic Bioscience A/S, H2 2017
    Osteoarthritis-Pipeline by Novartis AG, H2 2017
    Osteoarthritis-Pipeline by NovelMed Therapeutics Inc, H2 2017
    Osteoarthritis-Pipeline by Osteologix Holdings Plc, H2 2017
    Osteoarthritis-Pipeline by Pfizer Inc, H2 2017
    Osteoarthritis-Pipeline by Pharmalink AB, H2 2017
    Osteoarthritis-Pipeline by Philogen SpA, H2 2017
    Osteoarthritis-Pipeline by PhytoHealth Corp, H2 2017
    Osteoarthritis-Pipeline by PLx Pharma Inc, H2 2017
    Osteoarthritis-Pipeline by ProteoThera Inc, H2 2017
    Osteoarthritis-Pipeline by Regeneus Ltd, H2 2017
    Osteoarthritis-Pipeline by Regulaxis SAS, H2 2017
    Osteoarthritis-Pipeline by Rottapharm Biotech Srl, H2 2017
    Osteoarthritis-Pipeline by Samumed LLC, H2 2017
    Osteoarthritis-Pipeline by Seikagaku Corp, H2 2017
    Osteoarthritis-Pipeline by Stelis Biopharma Pvt Ltd, H2 2017
    Osteoarthritis-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
    Osteoarthritis-Pipeline by TissueGene Inc, H2 2017
    Osteoarthritis-Pipeline by Traverse Biosciences Inc, H2 2017
    Osteoarthritis-Pipeline by Unity Biotechnology Inc, H2 2017
    Osteoarthritis-Pipeline by Yooyoung Pharm Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Yuhan Corp, H2 2017
    Osteoarthritis-Pipeline by Yungjin Pharm Co Ltd, H2 2017
    Osteoarthritis-Pipeline by Zimmer Biomet Holdings Inc, H2 2017
    Osteoarthritis-Dormant Projects, H2 2017
    Osteoarthritis-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Osteoarthritis-Dormant Projects, H2 2017 (Contd..2), H2 2017
    Osteoarthritis-Dormant Projects, H2 2017 (Contd..3), H2 2017
    Osteoarthritis-Dormant Projects, H2 2017 (Contd..4), H2 2017
    Osteoarthritis-Dormant Projects, H2 2017 (Contd..5), H2 2017
    Osteoarthritis-Discontinued Products, H2 2017
    Osteoarthritis-Discontinued Products, H2 2017 (Contd..1), H2 2017

    List of Figures
    Number of Products under Development for Osteoarthritis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    4P-Pharma SAS
    AbbVie Inc
    Abiogen Pharma SpA
    Ablynx NV
    Amgen Inc
    Amura Holdings Ltd
    Anterogen Co Ltd
    Asahi Kasei Pharma Corp
    Axsome Therapeutics Inc
    Biopharm GmbH
    Bone Therapeutics SA
    Can-Fite BioPharma Ltd
    Cardax Inc
    Cellular Biomedicine Group Inc
    Corestem Inc
    Dong-A Socio Holdings Co Ltd
    Eli Lilly and Company
    Evgen Pharma Plc
    Galapagos NV
    Gemphire Therapeutics Inc
    Genequine Biotherapeutics GmbH
    GlaxoSmithKline Plc
    InKemia IUCT Group SA
    International Stem Cell Corp
    Jeil Pharmaceutical Co Ltd
    K-Stemcell Co Ltd
    Kang Stem Biotech Co Ltd
    Lateral Pharma Pty Ltd
    Levolta Pharmaceuticals Inc
    LG Chem, Ltd.
    Marina Biotech Inc
    Medivir AB
    Merck KGaA
    Mesoblast Ltd
    Mor Research Application Ltd
    Nordic Bioscience A/S
    Novartis AG
    NovelMed Therapeutics Inc
    Osteologix Holdings Plc
    Pfizer Inc
    Pharmalink AB
    Philogen SpA
    PhytoHealth Corp
    PLx Pharma Inc
    ProteoThera Inc
    Regeneus Ltd
    Regulaxis SAS
    Rottapharm Biotech Srl
    Samumed LLC
    Seikagaku Corp
    Stelis Biopharma Pvt Ltd
    Takeda Pharmaceutical Company Ltd
    TissueGene Inc
    Traverse Biosciences Inc
    Unity Biotechnology Inc
    Yooyoung Pharm Co Ltd
    Yuhan Corp
    Yungjin Pharm Co Ltd
    Zimmer Biomet Holdings Inc

    Request for Sample

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//osteoarthritis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments